Gilead Sciences Inc
-
FDA approves Gilead Sciences Inc’s Descovy to reduce the risk of HIV infection
Oct 4, 2019The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc’s Descovy to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men. The approval does not include... -
Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal
Aug 28, 2017News Hour: Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class...
